JP2012509258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509258A5 JP2012509258A5 JP2011536348A JP2011536348A JP2012509258A5 JP 2012509258 A5 JP2012509258 A5 JP 2012509258A5 JP 2011536348 A JP2011536348 A JP 2011536348A JP 2011536348 A JP2011536348 A JP 2011536348A JP 2012509258 A5 JP2012509258 A5 JP 2012509258A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- substituted
- alkyl
- peg
- cationic lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002105 nanoparticle Substances 0.000 claims 24
- -1 amino, substituted amino Chemical group 0.000 claims 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 235000012000 cholesterol Nutrition 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 4
- 229940106189 ceramide Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 230000000799 fusogenic effect Effects 0.000 claims 3
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108091027076 Spiegelmer Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- UWYSVYIRGIUDSC-UHFFFAOYSA-N CC(C)CCCC(C)C(CC=C)C(C)(CC1)CC2C1C(C)(CCC(C1)OC(COCCOCCNC(C(CCCCNC3NC3N)NC(N)=N)=O)=O)C1=CC2 Chemical compound CC(C)CCCC(C)C(CC=C)C(C)(CC1)CC2C1C(C)(CCC(C1)OC(COCCOCCNC(C(CCCCNC3NC3N)NC(N)=N)=O)=O)C1=CC2 UWYSVYIRGIUDSC-UHFFFAOYSA-N 0.000 description 1
- IRENVDDCYYVIBT-UHFFFAOYSA-N CC1C(N(C)CCC2)N2CCCC1 Chemical compound CC1C(N(C)CCC2)N2CCCC1 IRENVDDCYYVIBT-UHFFFAOYSA-N 0.000 description 1
- DWXIDAJNMISYJH-UHFFFAOYSA-N CCC(C1OC1N)N=C=N Chemical compound CCC(C1OC1N)N=C=N DWXIDAJNMISYJH-UHFFFAOYSA-N 0.000 description 1
- BWMDMTSNSXYYSP-UHFFFAOYSA-N CCCNC(N)=N Chemical compound CCCNC(N)=N BWMDMTSNSXYYSP-UHFFFAOYSA-N 0.000 description 1
- 0 CC[P@](NCCNC(N)=N)(N=CCC=[O+]CCC(CC(CCC1(C)C2CCC3(C)C(C)C(C)CCCC(C)C)CC1=CCC2C3C=C)=O)=*=CCNC(*)=N Chemical compound CC[P@](NCCNC(N)=N)(N=CCC=[O+]CCC(CC(CCC1(C)C2CCC3(C)C(C)C(C)CCCC(C)C)CC1=CCC2C3C=C)=O)=*=CCNC(*)=N 0.000 description 1
- APKFDBVGPJCXTC-UHFFFAOYSA-N CN1C(CCC2)N2CCC1 Chemical compound CN1C(CCC2)N2CCC1 APKFDBVGPJCXTC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11530708P | 2008-11-17 | 2008-11-17 | |
| US61/115,307 | 2008-11-17 | ||
| PCT/US2009/052462 WO2010056403A1 (en) | 2008-11-17 | 2009-07-31 | Branched cationic lipids for nucleic acids delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509258A JP2012509258A (ja) | 2012-04-19 |
| JP2012509258A5 true JP2012509258A5 (enExample) | 2012-07-19 |
Family
ID=42170237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536348A Withdrawn JP2012509258A (ja) | 2008-11-17 | 2009-07-31 | 核酸送達系のための分岐カチオン性脂質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110305769A1 (enExample) |
| EP (1) | EP2350296A4 (enExample) |
| JP (1) | JP2012509258A (enExample) |
| CN (1) | CN102216462A (enExample) |
| CA (1) | CA2742689A1 (enExample) |
| TW (1) | TW201019969A (enExample) |
| WO (1) | WO2010056403A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201021853A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| WO2013021143A1 (fr) | 2011-08-10 | 2013-02-14 | Adocia | Solution injectable d'au moins une insuline basale |
| EP2766482B1 (en) | 2011-10-11 | 2016-12-07 | The Brigham and Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| CA2853689C (en) * | 2011-11-04 | 2020-06-30 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| CN102516534B (zh) * | 2011-11-14 | 2013-11-20 | 上海交通大学 | 可降解为精胺的聚阳离子及其合成方法、纳米颗粒 |
| US9198971B2 (en) | 2012-01-09 | 2015-12-01 | Adocia | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
| GB201215289D0 (en) * | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
| AU2013355258A1 (en) | 2012-12-07 | 2015-06-11 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| ES3032935T3 (en) * | 2013-10-22 | 2025-07-29 | Translate Bio Inc | Lipid formulations for delivery of messenger rna |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| CN104922068B (zh) * | 2015-05-22 | 2017-10-13 | 江苏凯基生物技术股份有限公司 | 一种Decoy核酸阳离子脂质体载体及其制备方法 |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| KR102764250B1 (ko) | 2015-09-14 | 2025-02-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 지질양이온성 덴드리머 및 이의 용도 |
| EP3368089B1 (en) | 2015-10-26 | 2025-11-05 | Translate Bio Ma, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
| US10654875B2 (en) | 2015-11-12 | 2020-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| CN107951862B (zh) * | 2016-10-17 | 2021-03-12 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| WO2018081817A2 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| CA3059321A1 (en) * | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| CA3071968A1 (en) | 2017-08-04 | 2019-02-07 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| AU2019207626B2 (en) * | 2018-01-10 | 2023-10-05 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| US20210363518A1 (en) * | 2018-03-19 | 2021-11-25 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| US20210322575A1 (en) * | 2018-09-28 | 2021-10-21 | Nutcracker Therapeutics, Inc. | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery |
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| WO2021011692A1 (en) | 2019-07-17 | 2021-01-21 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| US20230098031A1 (en) * | 2019-12-11 | 2023-03-30 | The General Hospital Corporation | Methods for cell imaging |
| US20230062603A1 (en) * | 2020-01-07 | 2023-03-02 | Translate Bio Ma, Inc. | Formulations for delivery of oligonucleotides to lung cells |
| AU2021206510A1 (en) * | 2020-01-08 | 2022-08-04 | Microvascular Therapeutics, Llc | Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery |
| KR20230002300A (ko) * | 2020-01-21 | 2023-01-05 | 이더알엔에이 이뮤노테라피스 엔브이 | 지질 나노입자 |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| WO2021216431A1 (en) | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Benzyloxy phosph(on)ate compounds |
| EP4143199B1 (en) | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| CN114315606B (zh) * | 2020-12-29 | 2023-12-26 | 李斌 | 一种脂样分子及其应用 |
| CN121517316A (zh) * | 2021-05-06 | 2026-02-13 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离阳离子脂质 |
| WO2023107920A1 (en) * | 2021-12-07 | 2023-06-15 | The Trustees Of The University Of Pennsylvania | Anisamide-containing lipids and compositions and methods of use thereof |
| CN114306369B (zh) * | 2021-12-23 | 2023-12-26 | 北京悦康科创医药科技股份有限公司 | 一种硫代寡核苷酸注射液及其制备方法 |
| WO2026158650A1 (zh) * | 2025-01-26 | 2026-07-30 | 上海药明生物技术有限公司 | 非对称分枝型peg修饰的脂质化合物、其制备方法及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972600A (en) * | 1992-04-03 | 1999-10-26 | The Regents Of The University Of California | Separation of active complexes |
| US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
| US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| AU723998B2 (en) * | 1996-03-01 | 2000-09-07 | Centre National De La Recherche Scientifique | Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof |
| JP2001523480A (ja) * | 1997-11-20 | 2001-11-27 | バイカル インコーポレイテッド | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 |
| US6320017B1 (en) * | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| AU2003295561A1 (en) * | 2002-11-14 | 2004-06-15 | Genta Salus Llc | Inhibitory oliogonucleotides targeted to bcl-2 |
| US7713738B2 (en) * | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
| TWI257924B (en) * | 2003-09-22 | 2006-07-11 | Lipotek Inc | Cationic lipid for delivery function, and nanoparticle comprising the same |
| WO2007056861A1 (en) * | 2005-11-18 | 2007-05-24 | Protiva Biotherapeutics, Inc. | Sirna silencing of influenza virus gene expression |
| WO2008043366A2 (en) * | 2006-10-13 | 2008-04-17 | Københavns Universitet | Three-domain compounds for transmembrane delivery |
| TW201021853A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
| WO2010057150A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable polymeric lipids for nucleic acids delivery systems |
-
2009
- 2009-07-31 EP EP09826479A patent/EP2350296A4/en not_active Withdrawn
- 2009-07-31 CA CA2742689A patent/CA2742689A1/en not_active Abandoned
- 2009-07-31 US US13/129,495 patent/US20110305769A1/en not_active Abandoned
- 2009-07-31 WO PCT/US2009/052462 patent/WO2010056403A1/en not_active Ceased
- 2009-07-31 TW TW098125815A patent/TW201019969A/zh unknown
- 2009-07-31 CN CN2009801458870A patent/CN102216462A/zh active Pending
- 2009-07-31 JP JP2011536348A patent/JP2012509258A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529912A5 (enExample) | ||
| JP2011520983A5 (enExample) | ||
| JP2012509366A5 (enExample) | ||
| JP2012509273A5 (enExample) | ||
| DK2431466T3 (en) | Single-stranded nucleic acid molecule for the control of gene expression | |
| US9074208B2 (en) | Modified siRNA molecules and uses thereof | |
| US9006191B2 (en) | Silencing of polo-like kinase expression using interfering RNA | |
| JP2012509272A5 (enExample) | ||
| US20070218122A1 (en) | siRNA silencing of influenza virus gene expression | |
| US9035039B2 (en) | Compositions and methods for silencing SMAD4 | |
| JP7244424B2 (ja) | エンドソーム切断可能なリンカー | |
| AU2016201913A1 (en) | Compositions and methods for silencing aldehyde dehydrogenase | |
| CA2979998A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| JP2012532839A5 (enExample) | ||
| RU2010144531A (ru) | Модифицированная липидами двухцепочечная рнк, обладающая мощным эффектом рнк-интерференции | |
| JP2017500277A5 (enExample) | ||
| AU2013203219B2 (en) | MODIFIED siRNA MOLECULES AND USES THEREOF | |
| RU2010136047A (ru) | КАТИОННЫЕ siPНК, СИНТЕЗ И ПРИМЕНЕНИЕ В РНК-ИНТЕРФЕРЕНЦИИ | |
| CN120077134A (zh) | 靶向apoc3的多核酸分子及其用途 | |
| Zenkova et al. | Site-specific artificial ribonucleases: conjugates of oligonucleotides with catalytic groups | |
| AU2013202970A1 (en) | Silencing of polo-like kinase expression using interfering RNA | |
| RU2013114396A (ru) | Антисмысловые нуклеиновые кислоты |